Movano health provides update on fda review of eviemed ring

The company continues to work closely with the fda to bring this pioneering healthcare product to market pleasanton, calif. , oct. 10, 2024 /prnewswire/ -- movano health  (nasdaq: move) announced today that the company recently received additional clarifying questions from the fda related to medical aspects of the eviemed ring, as part of the final phase of the company's 510(k) application review process.
MOVE Ratings Summary
MOVE Quant Ranking